Company Profile

Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows:
- dialysis treatment (46.8%; Fresenius Medical Care): sales of equipment for hemodialysis, pediatric dialysis, peritoneal dialysis, dialysis services, etc.;
- hospital administration and engineering (34.2%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.;
- perfusion and clinical nutrition (19%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc.
Net sales are distributed geographically as follows: Europe (45%), North America (38.3%), Asia/Pacific (10.5%), Latin America (4.9%) and Africa (1.3%).

Source: Cofisem - Last Update: 2023-05-18

Key Executives
Chairman of the Management Board Michael Sen
Member of the Management Board Sebastian Biedenkopf
Member of the Management Board Francesco De Meo
Member of the Management Board Ernst Wastler
Chief Financial Officer Sara Hennicken
Human Resources Director Sebastian Biedenkopf
General Counsel Sebastian Biedenkopf
Investor Relations Director Markus Georgi
VP, Communication Matthias Link

Source: Cofisem - Last Update: 2023-05-02

Key Figures
Millenium 2022 2021 2020 2019 2018
Net sales 40,840,000 37,520,000 36,277,000 35,409,000 33,530,000
Income from ordinary activities 40,840,000 37,520,000 36,277,000 35,409,000 33,530,000
Operating income 3,321,000 4,158,000 4,385,000 4,631,000 5,251,000
Cost of financial indebtedness net 507,000 506,000 659,000 719,000 587,000
Equity-accounted companies contribution to income
Net profit from discontinued activities
Net income 2,117,000 2,819,000 2,823,000 3,029,000 3,714,000
Net income (Group share) 1,372,000 1,818,000 1,707,000 1,883,000 2,027,000
Fiscal year end 12.22 12.21 12.2 12.19 12.18
Length of fiscal year (month) 12 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards

Source: Cofisem - Last Update: 2023-05-18

Shareholder information
Institutional shareholders 61 %
Else Kröner-Fresenius Foundation 27 %
Other shareholders 12 %

Source: Cofisem - Last Update: 2023-05-18

Please contact for Company Profile support.

Quotazioni, Book, Dividendi, Documenti Societari, Corporate Governance, Internal Dealing di Fresenius

The Exchange accepts no responsability for the content of the website you are now accessing or for any reliance placed by you or any person on the information contained on it.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.

You will be redirected in five seconds.